Jump Financial LLC Purchases 39,556 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Jump Financial LLC increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 3,563.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 40,666 shares of the biotechnology company's stock after purchasing an additional 39,556 shares during the quarter. Jump Financial LLC owned 0.09% of United Therapeutics worth $8,942,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of UTHR. Cambridge Investment Research Advisors Inc. grew its position in shares of United Therapeutics by 9.0% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 1,705 shares of the biotechnology company's stock valued at $385,000 after purchasing an additional 141 shares during the last quarter. Raymond James & Associates increased its position in United Therapeutics by 1.7% during the third quarter. Raymond James & Associates now owns 28,054 shares of the biotechnology company's stock worth $6,337,000 after buying an additional 471 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in United Therapeutics by 48.8% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 2,345 shares of the biotechnology company's stock worth $530,000 after buying an additional 769 shares in the last quarter. Advisor Partners II LLC raised its holdings in shares of United Therapeutics by 7.7% in the third quarter. Advisor Partners II LLC now owns 1,339 shares of the biotechnology company's stock worth $302,000 after acquiring an additional 96 shares during the last quarter. Finally, Park Avenue Securities LLC purchased a new stake in shares of United Therapeutics in the third quarter valued at $303,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the company's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the transaction, the director now directly owns 4,185 shares of the company's stock, valued at approximately $1,087,723.35. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,756.70. The disclosure for this sale can be found here. Insiders sold 151,230 shares of company stock valued at $36,040,995 over the last 90 days. Corporate insiders own 12.50% of the company's stock.

United Therapeutics Trading Down 0.7 %

UTHR stock traded down $1.78 during trading on Friday, reaching $264.27. 391,702 shares of the stock traded hands, compared to its average volume of 578,697. The firm has a market capitalization of $11.72 billion, a PE ratio of 12.50 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The business's 50 day moving average price is $240.51 and its 200-day moving average price is $230.69. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $269.81.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million during the quarter, compared to analysts' expectations of $620.31 million. During the same quarter in the previous year, the business earned $4.86 EPS. The company's revenue for the quarter was up 33.7% on a year-over-year basis. As a group, sell-side analysts forecast that United Therapeutics Co. will post 24.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on UTHR shares. Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research note on Thursday, May 2nd. Wedbush reaffirmed an "outperform" rating and issued a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. HC Wainwright reissued a "buy" rating and set a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. SVB Leerink assumed coverage on United Therapeutics in a report on Monday, February 5th. They set an "outperform" rating and a $330.00 price objective on the stock. Finally, The Goldman Sachs Group upped their target price on United Therapeutics from $218.00 to $240.00 and gave the company a "neutral" rating in a research note on Friday, May 3rd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $308.78.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.